IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

被引：0

作者：

Hussain, Maha H. A.

Powles, Thomas

Albers, Peter

Castellano, Daniel

Daneshmand, Siamak

Gschwend, Juergen

Nishiyama, Hiroyuki

Oudard, Stephane

Tayama, Darren

Davarpanah, Nicole N.

Degaonkar, Viraj

Shi, Yi

Mariathasan, Sanjeev

Grivas, Petros

Peter, H. O.

Rosenberg, Jonathan E.

Geynisman, Daniel M.

Hoffman-Censits, Jean H.

Peter Petrylak, Daniel

Bellmunt, Joaquim

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Queen Mary Univ London, Barts Canc Inst, London, England

[3] Heinrich Heine Univ, Dept Urol, Dusseldorf, Germany

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Tech Univ Munich, Dept Urol, Munich, Germany

[7] Univ Tsukuba, Tsukuba, Ibaraki, Japan

[8] Georges Pompidou Hosp, Paris, France

[9] Genentech Inc, San Francisco, CA USA

[10] Univ Washington, Seattle, WA 98195 USA

[11] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA

[12] Mem Sloan Kettering Canc, New York, NY USA

[13] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[14] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[15] Yale Univ, Smilow Canc Ctr, New Haven, CT USA

[16] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5000

引用

页数：2